{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:27:33Z","timestamp":1775759253060,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Available data on antipsychotic-induced metabolic risks are often constrained by potential confounding effects due to prior antipsychotic treatment. In this study, we assessed the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia in the European first-episode schizophrenia trial (EUFEST). Overall baseline prevalence of metabolic syndrome (MetS) was 6.0%, with similar rates observed in the antipsychotic-naive patients (5.7%, 9\/157) and in the other patients with only a brief prior exposure to antipsychotics (6.1%, 20\/326). These results are consistent with the MetS prevalence rate estimated in a general population of similar age. Examination of individual risk factors showed 58.5% of subjects had one or more elevated metabolic risks at baseline: 28.5% demonstrated suboptimal HDL; 24.2% hypertension; 17.7% hypertriglyceridemia; 8.2% abdominal obesity; 7.3% hyperglycaemia. Increase in body weight (kg\/month) occurred in patients treated with haloperidol (0.62 s.e. 0.11), amisulpride (0.76 s.e. 0.08), olanzapine (0.98 s.e. 0.07) and quetiapine (0.58 s.e. 0.09), which was significantly greater than that in the ziprasidone group (0.18 s.e. 0.10). The incidence rate of new diabetes cases over a 52-wk follow-up period was 0.82% (4\/488). More patients experienced worsening rather than improvement of hypertriglyceridemia or hyperglycaemia in all treatment groups. Our findings suggest that in first-episode, partially antipsychotic-naive patients, the baseline prevalence rate of MetS appears to be no higher than that in the general population, but serious underlying individual risk factors nevertheless existed.<\/jats:p>","DOI":"10.1017\/s1461145712001241","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T08:18:06Z","timestamp":1355991486000},"page":"987-995","source":"Crossref","is-referenced-by-count":78,"title":["Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial"],"prefix":"10.1093","volume":"16","author":[{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"first","affiliation":[{"name":"Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia O.","family":"Siu","sequence":"additional","affiliation":[{"name":"Data Power Inc., New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bod\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Pappadopulos","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur N.","family":"Karayal","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the EUFEST study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,6,1]]},"reference":[{"key":"2019101113395598900_ref1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1262-3636(07)70067-8","article-title":"The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome: the French D. E. S.I. R. study","volume":"29","author":"Balkau","year":"2003","journal-title":"Diabetes Metab"},{"key":"2019101113395598900_ref2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.schres.2008.09.018","article-title":"Course of illness in a sample of 265 patients with first-episode psychosis-five year follow-up of the Danish OPUS trials","volume":"107","author":"Bertelsen","year":"2009","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"2019101113395598900_ref5","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"J Am Med Assoc"},{"key":"2019101113395598900_ref6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2019101113395598900_ref7","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.yic.0000201496.23259.85","article-title":"Metabolic abnormalities associated with second generation antipsychotics: facts or fiction? Development of guidelines for screening and monitoring","volume":"21","author":"De Hert","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"2019101113395598900_ref8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"100","author":"De Hert","year":"2008","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/eurpub\/ckn056","article-title":"Identifying metabolic syndrome without blood tests in young adults \u2013 the Terneuzen birth cohort","volume":"18","author":"de Kroon","year":"2008","journal-title":"Eur J Public Health"},{"key":"2019101113395598900_ref10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despres","year":"2006","journal-title":"Nature"},{"key":"2019101113395598900_ref11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"2019101113395598900_ref12","first-page":"1","article-title":"Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity and body mass index","volume":"13","author":"Ervin","year":"2009","journal-title":"Natl Health Stat Rep"},{"key":"2019101113395598900_ref13","volume-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2004"},{"key":"2019101113395598900_ref14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"Fleischhacker","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2019101113395598900_ref15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European first episode schizophrenia trial (EUFEST): rationale and design of the trial","volume":"7","author":"Fleischhacker","year":"2005","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey","volume":"287","author":"Ford","year":"2002","journal-title":"J Am Med Assoc"},{"key":"2019101113395598900_ref17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr Diab Rep"},{"key":"2019101113395598900_ref18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/08039488.2010.522729","article-title":"Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study","volume":"65","author":"Johnsen","year":"2011","journal-title":"Nord J Psychiatry"},{"key":"2019101113395598900_ref19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/archpediatrics.2009.3","article-title":"Prevalence of risk factors for metabolic syndromes in adolescents","volume":"163","author":"Johnson","year":"2009","journal-title":"Arch Pediatr Med"},{"key":"2019101113395598900_ref20","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/S0140-6736(08)60731-X","article-title":"Metabolic syndrome \u2013 what is the clinical usefulness?","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"2019101113395598900_ref21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"2019101113395598900_ref22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1370\/afm.1137","article-title":"Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999\u20132006","volume":"8","author":"Kulina","year":"2010","journal-title":"Ann Fam Med"},{"key":"2019101113395598900_ref23","first-page":"32","article-title":"The clinical implications of weight gain in schizophrenia","volume":"62","author":"Kurzthaler","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2019101113395598900_ref24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"35","author":"Lieberman","year":"2005","journal-title":"N Eng J Med"},{"key":"2019101113395598900_ref27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2019101113395598900_ref26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/eurheartj\/ehm576","article-title":"Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study","volume":"29","author":"Mattsson","year":"2008","journal-title":"Eur Heart J"},{"key":"2019101113395598900_ref28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2005.07.015","article-title":"The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome","volume":"80","author":"Meyer","year":"2005","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders \u2013 A systematic review and meta-analysis","author":"Mitchell","year":"2011","journal-title":"Schizophr Bull"},{"key":"2019101113395598900_ref30","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients","author":"Mitchell","year":"2012","journal-title":"Schizophr Bull"},{"key":"2019101113395598900_ref31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol Med"},{"key":"2019101113395598900_ref32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2337\/dc10-0879","article-title":"Persistent increase of prevalence of metabolic syndrome among us adults: NHANES III to NHANES 1999\u20132006","volume":"34","author":"Mozumdar","year":"2011","journal-title":"Diabetes Care"},{"key":"2019101113395598900_ref33","first-page":"337","article-title":"The metabolic effects of antipsychotic medications","volume":"59","author":"Newcomer","year":"2006","journal-title":"Can J Psychiatry"},{"key":"2019101113395598900_ref34","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"J Am Med Assoc"},{"key":"2019101113395598900_ref35","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"2019101113395598900_ref36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAF\u00c9 study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1176\/appi.ajp.2009.09070959","article-title":"Dropouts and missing data in psychiatric clinical trials","volume":"166","author":"Potkin","year":"2009","journal-title":"Am J Psychiatry"},{"key":"2019101113395598900_ref38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1373\/clinchem.2005.048611","article-title":"The metabolic syndrome: requiescat in pace","volume":"51","author":"Reaven","year":"2005","journal-title":"Clin Chem"},{"key":"2019101113395598900_ref39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2019101113395598900_ref40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":"Metabolic syndrome in first-episode schizophrenia \u2013 a randomized, double-blind controlled, short-term prospective study","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophr Res"},{"key":"2019101113395598900_ref41","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M. I. N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2019101113395598900_ref42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jama.284.3.311","article-title":"Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity","volume":"284","author":"Stamler","year":"2000","journal-title":"J Am Med Assoc"},{"key":"2019101113395598900_ref43","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"18","author":"Tschoner","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2019101113395598900_ref44","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.2337\/diabetes.52.10.2490","article-title":"Insulin sensitivity, insulin secretion and abdominal fat: the insulin resistance atherosclerosis study (IRAS) family study","volume":"52","author":"Wagenknecht","year":"2003","journal-title":"Diabetes"},{"key":"2019101113395598900_ref45","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1017\/S0954579498001667","article-title":"The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations","volume":"10","author":"Willett","year":"1998","journal-title":"Dev Psychopathol"},{"key":"2019101113395598900_ref46","volume-title":"Global Health Risks: Mortality and burden of disease attributable to selected major risks","author":"WHO","year":"2009"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/16\/5\/987\/30135343\/16-5-987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/16\/5\/987\/30135343\/16-5-987.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T16:43:38Z","timestamp":1570812218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/16\/5\/987\/715721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.1017\/s1461145712001241","relation":{},"ISSN":["1469-5111","1461-1457"],"issn-type":[{"value":"1469-5111","type":"electronic"},{"value":"1461-1457","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,6]]},"published":{"date-parts":[[2013,6,1]]}}}